The Latest Breaking News from LLY

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America’s retail landscape.

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.